Clinical

Videos

“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

Oral testosterone undecanoate shows promising results for first use in the real world

Articles

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug. 

Pivotal data for lumasiran in PH1 published in NEJM

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria. 

Nedosiran explored in primary hyperoxaluria type 3

FDA new drug application filing expected by the end of 2021. 

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

FDA approves androgen inhibitor for metastatic PCa

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

Blood test could guide treatment for kidney cancer

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-GuÃ©rin is currently unavailable from one manufacturer.

BCG for bladder cancer in short supply

Researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center in New York have successfully developed and tested a new prostate cancer screening method.

PSA, 5-ARIs help identify hard-to-diagnose PCa

Fesoterodine fumarate (Toviaz) appears to reduce urge urinary incontinence in patients with overactive bladder who had a suboptimal response to tolterodine tartrate extended release (Detrol LA), according to a phase IV study.

Drug reduces urge incontinence in OAB patients

Interim data from a phase III trial of a novel radiation agent in men with castration-resistant prostate cancer (CRPC) showed the agent's efficacy to be significantly sufficient to bring the trial to a halt at a planned interim analysis so as to be able offer the agent to men in the placebo arm.

Drug Therapy